Iteos Therapeutics Inc (ITOS)

Currency in USD
10.15
+0.02(+0.20%)
Closed·
Showing Iteos historical data. For real-time data please try another search
Fair Value
Day's Range
10.1410.17
52 wk Range
4.8017.63
Key Statistics
Prev. Close
10.15
Open
10.14
Day's Range
10.14-10.17
52 wk Range
4.8-17.63
Volume
11.01M
Average Volume (3m)
1.34M
1-Year Change
2.01%
Book Value / Share
12.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
ITOS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Iteos Therapeutics Inc News & Analysis

Show more

Iteos Therapeutics Inc Company Profile

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company’s lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. As of August 28, 2025, iTeos Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Compare ITOS to Peers and Sector

Metrics to compare
ITOS
Peers
Sector
Relationship
P/E Ratio
−2.2x0.0x−0.7x
PEG Ratio
0.040.000.00
Price/Book
0.9x0.0x2.6x
Price / LTM Sales
-0.0x3.4x
Upside (Analyst Target)
−0.5%0.0%37.8%
Fair Value Upside
Unlock0.0%5.5%Unlock

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-1.28 / -0.8882
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ITOS Income Statement

People Also Watch

29.98
CRML
+28.78%
7.1300
ATON
+9.02%
43.060
QBTS
+6.01%
3.200
PGEN
-0.31%
21.750
SMMT
-5.15%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.